TABLE 2-A1.
Characteristics of the HIV-uninfected and HIV-infected individuals taking antiretroviral therapy.
| Variable | HIV-uninfected | HIV-infected taking ART | p |
|---|---|---|---|
| Men | |||
| N | 23 | 17 | 0.975 |
| % | 20.2 | 20.0 | |
| Age, years | 53.4 ± 5.5 | 53.0 ± 5.3 | 0.636 |
| Urban N (%) | |||
| N | 46 | 35 | 0.906 |
| % | 40.4 | 41.2 | |
| Anthropometry | |||
| WC | 91.6 | 82.6 | < 0.001 |
| cm | 70.5; 123 | 65.50; 109 | |
| BMI, | 27.4 | 23.0 | < 0.001 |
| kg/m2 | 18.0; 44.5 | 15.6; 35.9 | |
| Cardiovascular measurements | |||
| SBP, mmHg | 133 ± 21 | 125 ± 23 | 0.014 |
| DBP, mmHg | 88 ± 12 | 82 ± 13 | 0.001 |
| PP, mmHg | 45 ± 14 | 43 ± 15 | 0.308 |
| MAP, mmHg | 103 ± 14 | 97 ± 15 | 0.003 |
| cSBP, mmHg | 129 ± 18 | 118 ± 16 | < 0.001 |
| Biochemical variables | |||
| TC, mmol/L | 4.54 ± 1.16 | 4.50 ± 0.92 | 0.794 |
| LDL-c, mmol/L | 2.79 ± 1.02 | 2.61 ± 0.87 | 0.201 |
| TG | 1.18 | 1.14 | 0.689 |
| mmol/L | 0.53; 2.85 | 0.54; 2.35 | |
| HDL-c | 1.25 | 1.34 | 0.148 |
| mmol/L | 0.69; 2.27 | 0.79; 2.53 | |
| Glucose, mmol/L | 5.34 | 5.15 | 0.491 |
| mmol/L | 3.85; 9.03 | 4.26; 6.10 | |
| HbA1c | 5.92 | 5.41 | < 0.001 |
| % | 5.00; 8.80 | 4.90; 6.20 | |
| CRP | 1.11 | 1.71 | 0.160 |
| mg/L | 0.05; 16.1 | 0.04; 44.7 | |
| γ-glutamyltransferase | 23.2 | 26.7 | 0.538 |
| U/L | 1.46; 256 | 1.24; 225 | |
| HIV-related parameters | |||
| CD4+ cell count, cell/mm3 | - | 525 ± 264 | - |
| ≤ 500 cells/mm3 | - | - | |
| N | - | 37/78 | - |
| % | - | 47.4 | - |
| ≤ 200 cells/mm3 | - | - | - |
| N | - | 7/78 | - |
| % | - | 8.97 | - |
| Renal function | |||
| Scr, µmol/L | 55.9 ± 11.4 | 56.4 ± 12.6 | 0.787 |
| CrCl, | 116 | 100 | 0.002 |
| mL/min | 72.0; 207 | 56.0; 167 | |
| CrCl, < 50 mL/min | 0.245 | ||
| N | 0/113 | 1/84 | |
| % | 0.00 | 1.09 | |
| eGFR, | 103 | 102 | 0.504 |
| mL/min/1.73 m2 | 83.2; 123 | 79.2; 120 | |
| eGFR, < 90 mL/min/1.73 m2, N (%) | 0.523 | ||
| N | 14 | 8 | |
| % | 12.3 | 9.41 | |
| uACR | 1.43 | 1.89 | 0.109 |
| mg/mmol | 0.43; 14.6 | 0.48; 22.6 | |
| uACR, 3 mg/mmol – 30 mg/mmol, N (%) | 0.232 | ||
| N | 18/102 | 19/76 | |
| % | 17.7 | 25.0 | |
| Health behaviours | |||
| Self-reported alcohol use, N (%) | 0.961 | ||
| N | 34/113 | 25/84 | |
| % | 30.1 | 29.8 | |
| Self-reported tobacco use, N (%) | 0.667 | ||
| N | 41/113 | 33/84 | |
| % | 36.3 | 39.3 | |
| Medication use | |||
| Antihypertensives | 0.003 | ||
| N | 35 | 11 | |
| % | 30.7 | 12.9 | |
| Diuretics | 0.023 | ||
| N | 38 | 16 | |
| % | 33.3 | 18.8 | |
| Statins | 0.122 | ||
| N | 6 | 1 | |
| % | 5.3 | 1.2 | |
| Anti-inflammatories | 0.991 | ||
| N | 8 | 6 | |
| % | 7.0 | 7.1 | |
| Antidiabetic agents | 0.005 | ||
| N | 10 | 0 | |
| % | 8.8 | 0.0 | |
| Anticoagulants | 0.200 | ||
| N | 9 | 3 | |
| % | 7.9 | 3.5 | |
| ≥ 5 years on ART | - | ||
| N | - | 38/59 | |
| % | - | 64.4 | |
| Metabolic syndrome | 0.024 | ||
| N | 50 | 24 | |
| % | 43.9 | 24.2 | |
Data are arithmetic mean ± s.d. or geometric mean (5th and 95th percentile intervals) for logarithmically transformed variables.
HIV-uninfected, N = 114; HIV-infected taking ART, N = 85.
s.d., standard deviation; CI, confidence interval; HIV, human immunodeficiency virus; N, number of participants; WC, waist circumference; BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; PP, pulse pressure; MAP, mean arterial pressure; cSBP, central systolic blood pressure; TC, total cholesterol; LDL-cholesterol, low density lipoprotein cholesterol; HDL-cholesterol, high-density lipoprotein cholesterol; CRP, C-reactive protein; SCr, serum creatinine; CrCl, creatinine clearance; eGFR, estimated glomerular filtration rate; uACR, urinary albumin-creatinine ratio; Med, medication; ART, antiretroviral therapy; N, number.